SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Nabriva Therapeutics Q1 EPS $(0.290) Misses $(0.260) Estimate, Sales $1.703M Beat $460.000K Estimate

Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.290) per share which missed the analyst consensus estimate of $(0.260) by 11.54 percent. This is unchanged from the same period last year. The company

Benzinga · 05/11/2020 20:07

Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.290) per share which missed the analyst consensus estimate of $(0.260) by 11.54 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.703 million which beat the analyst consensus estimate of $460.000 thousand by 270.22 percent. This is the same as the same period last year.